Evotec and Plectonic Biotech Research Collaboration
Analysis based on 9 articles · First reported Sep 02, 2026 · Last updated Sep 02, 2026
The collaboration is a positive development for Evotec, potentially strengthening its oncology pipeline and validating its BiTco platform, which could enhance its attractiveness to partners and investors. For Plectonic, the partnership with a major player like Evotec provides validation and resources to advance its LOGIBODY technology, though financial terms were not disclosed and the impact is likely modest in the near term.
On September 2, 2026, Evotec and Plectonic Biotech announced a research collaboration to explore a novel immunotherapy approach for solid tumors. The collaboration combines Plectonic's programmable LOGIBODY technology, which uses logic-gated DNA-protein therapeutics to recognize tumors via a predefined multi-antigen signature before engaging T cells, with Evotec's proprietary BiTco platform, based on a non-blocking CD2 antibody that provides costimulatory signals to enhance T cell activity and persistence. The goal is to improve the precision and potency of T-cell-engaging therapies in solid tumors, which represent about 90% of all cancers. The collaboration will generate preclinical proof-of-concept data. Evotec's Chief Scientific Officer, Cord Dohrmann, and Plectonic's CEO, Klaus Wagenbauer, both expressed optimism about the potential of combining their technologies to address challenges in tumor selectivity and safety.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard